Cargando…
First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
OBJECTIVES: To compare the first-year results of patients with active neovascular age-related macular degeneration (nAMD) under intravitreal ranibizumab (IVR) treatment who did and did not undergo cataract surgery. MATERIALS AND METHODS: The records of 72 patients with active nAMD were reviewed retr...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416477/ https://www.ncbi.nlm.nih.gov/pubmed/30829020 http://dx.doi.org/10.4274/tjo.galenos.2018.76429 |
_version_ | 1783403361161183232 |
---|---|
author | Sül, Sabahattin Karalezli, Aylin Karabulut, Müjdat |
author_facet | Sül, Sabahattin Karalezli, Aylin Karabulut, Müjdat |
author_sort | Sül, Sabahattin |
collection | PubMed |
description | OBJECTIVES: To compare the first-year results of patients with active neovascular age-related macular degeneration (nAMD) under intravitreal ranibizumab (IVR) treatment who did and did not undergo cataract surgery. MATERIALS AND METHODS: The records of 72 patients with active nAMD were reviewed retrospectively. Group 1 consisted of 23 patients who underwent uncomplicated cataract surgery and continued with IVR treatment and group 2 consisted of 49 patients without cataract who received only IVR treatment. The groups were compared according to pretreatment and first year best spectacle-corrected visual acuity (BCVA), central foveal thickness (CFT), number of injections, and nAMD activity (presence of subretinal or intraretinal fluid). Logarithm of minimum angle of resolution (LogMAR) was used for the determination of visual acuity. Activity findings were evaluated with optical coherence tomography. RESULTS: Pretreatment BCVA was 0.94±0.21 in group 1 and 0.77±0.36 in group 2 (p=0.041). At the end of the first year, BCVA was 0.48±0.35 in group 1 and 0.49±0.33 in group 2 (p=0.902). BCVA change was 0.46±0.29 in group 1 and 0.28±0.31 in group 2 (p=0.026). Pretreatment CFT was 305±146 μm in group 1 and 340±120 μm in group 2 (p=0.292). At the end of the first year, CFT was 246±110 μm and 245±82 μm in group 2 (p=0.977). CFT change was 59±45 μm in group 1 and 92±97 μm in group 2 (p=0.135). Mean number of injections over 1 year was 6.2±1.9 in group 1 and 5.7±1.8 in group 2 (p=0.271). At the end of the first year, subretinal fluid was observed in 3 patients in group 1 (13%) and 5 patients in group 2 (10.2%) (p=0.721) and intraretinal fluid was present in 3 patients in group 1 (13%) and 4 patients in group 2 (8.2%) (p=0.515). CONCLUSION: Cataract surgery combined with IVR treatment yielded significant visual gain in patients with active nAMD. Anatomic results suggest that cataract surgery does not worsen nAMD. |
format | Online Article Text |
id | pubmed-6416477 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Galenos Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-64164772019-03-19 First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration Sül, Sabahattin Karalezli, Aylin Karabulut, Müjdat Turk J Ophthalmol Original Article OBJECTIVES: To compare the first-year results of patients with active neovascular age-related macular degeneration (nAMD) under intravitreal ranibizumab (IVR) treatment who did and did not undergo cataract surgery. MATERIALS AND METHODS: The records of 72 patients with active nAMD were reviewed retrospectively. Group 1 consisted of 23 patients who underwent uncomplicated cataract surgery and continued with IVR treatment and group 2 consisted of 49 patients without cataract who received only IVR treatment. The groups were compared according to pretreatment and first year best spectacle-corrected visual acuity (BCVA), central foveal thickness (CFT), number of injections, and nAMD activity (presence of subretinal or intraretinal fluid). Logarithm of minimum angle of resolution (LogMAR) was used for the determination of visual acuity. Activity findings were evaluated with optical coherence tomography. RESULTS: Pretreatment BCVA was 0.94±0.21 in group 1 and 0.77±0.36 in group 2 (p=0.041). At the end of the first year, BCVA was 0.48±0.35 in group 1 and 0.49±0.33 in group 2 (p=0.902). BCVA change was 0.46±0.29 in group 1 and 0.28±0.31 in group 2 (p=0.026). Pretreatment CFT was 305±146 μm in group 1 and 340±120 μm in group 2 (p=0.292). At the end of the first year, CFT was 246±110 μm and 245±82 μm in group 2 (p=0.977). CFT change was 59±45 μm in group 1 and 92±97 μm in group 2 (p=0.135). Mean number of injections over 1 year was 6.2±1.9 in group 1 and 5.7±1.8 in group 2 (p=0.271). At the end of the first year, subretinal fluid was observed in 3 patients in group 1 (13%) and 5 patients in group 2 (10.2%) (p=0.721) and intraretinal fluid was present in 3 patients in group 1 (13%) and 4 patients in group 2 (8.2%) (p=0.515). CONCLUSION: Cataract surgery combined with IVR treatment yielded significant visual gain in patients with active nAMD. Anatomic results suggest that cataract surgery does not worsen nAMD. Galenos Publishing 2019-02 2019-02-28 /pmc/articles/PMC6416477/ /pubmed/30829020 http://dx.doi.org/10.4274/tjo.galenos.2018.76429 Text en © Copyright 2019 by Turkish Ophthalmological Association | Turkish Journal of Ophthalmology, published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Sül, Sabahattin Karalezli, Aylin Karabulut, Müjdat First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration |
title | First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration |
title_full | First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration |
title_fullStr | First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration |
title_full_unstemmed | First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration |
title_short | First-Year Outcomes of Cataract Surgery Combined with Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration |
title_sort | first-year outcomes of cataract surgery combined with intravitreal ranibizumab injection in wet age-related macular degeneration |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416477/ https://www.ncbi.nlm.nih.gov/pubmed/30829020 http://dx.doi.org/10.4274/tjo.galenos.2018.76429 |
work_keys_str_mv | AT sulsabahattin firstyearoutcomesofcataractsurgerycombinedwithintravitrealranibizumabinjectioninwetagerelatedmaculardegeneration AT karalezliaylin firstyearoutcomesofcataractsurgerycombinedwithintravitrealranibizumabinjectioninwetagerelatedmaculardegeneration AT karabulutmujdat firstyearoutcomesofcataractsurgerycombinedwithintravitrealranibizumabinjectioninwetagerelatedmaculardegeneration |